Cathay International Holdings Ld Lansen reports annual results (1441U)
March 27 2019 - 4:01AM
UK Regulatory
TIDMCTI
RNS Number : 1441U
Cathay International Holdings Ld
27 March 2019
Cathay International Holdings Limited
("Cathay", the "Company" or together with its subsidiaries, the
"Group")
Lansen reports annual results for the year ended 31 December
2018
Hong Kong, 27 March 2019 - Cathay International Holdings Ltd.
(LSE: CTI.L), an operator and investor in the growing healthcare
sector in the People's Republic of China, today notes Lansen
Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), the Company's
50.68% owned subsidiary, has reported its annual results for the
year ended 31 December 2018 in accordance with the requirements of
its Hong Kong listing.
The full text of the Lansen Announcement can be found at
http://www3.hkexnews.hk/listedco/listconews/SEHK/2019/0327/LTN20190327105.pdf
and will also be made available at Announcements and Notices
section of Lansen's homepage at
http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.
As previously announced, Cathay will issue its Annual Results
for the year ended 31 December 2018 on Friday 29 March 2019.
-ENDS-
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
Consilium Strategic Communications
Mary-Jane Elliott/ Matthew Neal / Lindsey Neville Tel: +44 (0) 203 709 5700
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the healthcare sector in the People's Republic of China
(the "PRC"). The Group aims to leverage on investment opportunities
in the growing domestic demand for high quality healthcare products
in the PRC and build portfolio companies into market sector leaders
with competitive edge. Cathay has already demonstrated a track
record of identifying investment opportunities in this area
including: Lansen, a PRC specialty pharmaceutical company focused
on rheumatology and dermatology; Haizi, a PRC inositol
manufacturer; Natural Dailyhealth, a company engaged in production
and sales of plant extracts for use as key active ingredients in
healthcare products; and Botai, a company engaged in collagen
products.
The Group employs approximately 1,800 people across the PRC,
including over 20 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment in Shenzhen. For more
information please visit the Company's website:
http://www.cathay-intl.com.hk.
About Lansen
Lansen, whose shares are listed on the main board of the Hong
Kong Stock Exchange, is a 50.68% owned subsidiary of Cathay. Lansen
is engaged in the manufacture, distribution and development of
specialty prescription drugs for treatment of autoimmune disorder
in rheumatology and dermatology. Lansen specialises in disease
modifying anti-rheumatic drugs ("DMARDs") for treatment of
rheumatoid arthritis ("RA") in the PRC. Lansen has established an
extensive distribution network, covering more than 1,000 hospitals
in four municipalities, 25 provinces and cities in the PRC. For
more information please visit the Lansen's website:
http://www.lansen.com.cn/en/index.aspx.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSKMGZFNNNGLZG
(END) Dow Jones Newswires
March 27, 2019 04:01 ET (08:01 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2023 to Apr 2024